Natera (NTRA) announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC ...

Natera has begun the subject enrolment in the randomised Phase III SAGITTARIUS clinical trial designed to assess the ...

Currently trading with a volume of 643,596, the NTRA's price is up by 3.63%, now at $172.49. RSI readings suggest the stock ...

根据美国证券交易委员会的一份文件显示，Natera, Inc.（纳斯达克股票代码：NTRA）的执行董事长Matthew Rabinowitz最近出售了大量公司股票。该公司股票今年以来已上涨超过165%，目前在52周高点附近交易，价格为166.55美元。根据 InvestingPro ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC ...

Updates shares, adds Guardant comment. Guardant Health (NASDAQ:GH) rose 8.4% at least partly after a North California jury ...

AUSTIN, Texas, December 12, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the SAGITTARIUS ...

德克萨斯州奥斯汀讯——根据向美国证券交易委员会提交的4表格显示，Natera, Inc.（纳斯达克股票代码：NTRA）临床诊断总裁Solomon Moshkevich最近进行了一笔重大的公司股票交易。Moshkevich于2024年12月9日以加权平均价格166.5937美元每股的价格出售了4,858股Natera普通股。此次出售的总价值约为809,312美元。根据 InvestingPro ...

Natera, Inc. (NASDAQ:NTRA – Get Free Report) has earned an average rating of “Buy” from the seventeen ratings firms that are ...

The latest announcement is out from Natera ( (NTRA) ).

A jury awarded Guardant Health $292.5 million in damages related to a false-advertising and unfair-competition lawsuit that the oncology company brought against rival Natera in 2021.

According to Benzinga Pro, Natera's peer group average for short interest as a percentage of float is 5.09%, which means the ...